ImmunoCellular Therapeutics, Ltd. (OTC: IMUC) (IMUC), a biotechnology company, announced the filing of a provisional U.S. patent application relating to its novel vaccine technology targeting cancer stem cells. The vaccine technology is exclusively licensed from Cedars-Sinai Medical Center. The patent claims are broad and include compositions of peptides for cancer immunotherapy as well as methods for inducing immune responses against tumor antigens in cancer patients.
Wednesday, October 15, 2008
Patent application: cancer stem cell vaccine technology
ImmunoCellular Therapeutics Announces Filing Of Patent Application For A Novel Cancer Stem Cell Vaccine Technology, Medical News Today, October 12, 2008. The first paragraph: